Improved efficiency of budesonide nebulization using surface-active agents

Drug Delivery

Volumn 13, Issue 5, 2006, Pages 357-363

  Bouwman, A ^a   Heijstra, M ^a   Schaefer, N ^a   Duiverman, E ^b   Lesouef P ^a   Devadason, S ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Detergent; Ionic Charge; Nebulization; Particle size; Surfactants

Indexed keywords

BUDESONIDE; DETERGENT; SURFACTANT;

ARTICLE; DRUG EFFICACY; DRUG FORMULATION; LASER DIFFRACTION; NEBULIZATION; PARTICLE SIZE; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; BUDESONIDE; DETERGENTS; DRUG DELIVERY SYSTEMS; LASERS; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; REFRACTOMETRY; SOLUBILITY; SURFACE-ACTIVE AGENTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 33746811824     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540500458862     Document Type: Article

References (27)

1. Barry, P. W., and O'Callaghan, C. 1999. An in vitro analysis of the output of budesonide from different nebulizers. J. Allergy Clin. Immunol. 104:1168-1173.
2. Barry, P. W., and O'Callaghan, C. 1998. The output of budesonide from nebulizers. J. Allergy Clin. Immunol. 102:321-322.
3. Berg, E., Backstrom, K., Dhalback, M., and Nerbrink, O. 1988. Output and particle size distribution of Pulmicort suspension generated from MAD2 and Pariboy jet nebulizers. J. Aerosol Sci. 19: 1093-1096.
4. Berlinski, A., and Waldrep, J. C. 1997. Effect of aerosol delivery system and formulation on nebulized budesonide output. J. Aerosol Med. 10:307-318.
5. Bisgaard, H., Nikander, K., and Munch, E. 1998. Comparative study of budesonide as a nebulized suspension versus pressurized metered-dose inhaler in adult asthmatics (abstract). Resp. Med. 92:44-49.
6. Corcoran, T. E. Hitron, R. Humphrey, W., and Chigier, N. 2000. Optical measurement of nebulizer sprays: a quantitative comparison of diffraction, phase doppler interferometry and time of flight techniques. J. Aerosol Sci. 31(1):35-50.
7. Devadason, S. G., and LeSouëf, P. N. 1997. Principles of aerosol delivery. In The Pediatric Lung: Respiratory Pharmacology and Pharmacotherapy, ed. Wilmott, R. W. Basel, Switzerland: Birkhäuser Verlag.
8. Dolovich, M. B. 1989. Physical principles underlying aerosol therapy. J. Aerosol Med. 2:171-186.
9. Everard, M. L., and LeSouëf, P. N. 1999. Aerosol therapy and delivery systems. In Pediatric Respiratory Medicine, ed. Taussig, L. M., and Landau L. I. St. Louis, MO: Mosby.
10. Fajardo, C., Levin, D., Garcia, M., et al. 1998. Surfactant versus saline as a vehicle for corticosteroid delivery to the lungs of ventilated rabbits. Pediatr. Res. 43:542-547.
11. Heyder, J., Gebhart, J., Rudolf, G., et al. 1986. Deposition of particles in the human respiratory tract in the size range 0.005-15 mcm. J. Aerosol Sci. 17:811-825.
12. Ho, K. K. L., Kellaway, I. W., and Tredree, R. 1986. Particle size analysis of nebulised aerosols using Fraunhofer laser diffraction and inertial compaction methods. J. Pharm. Pharmacol. 38:26.
13. Hoekstra, M. O. 1997. Treatment of asthma in children; revised guidelines by pediatric pneumologists. Ned. Tijdschr. Geneesk 141:2223-2228.
14. Hvizdos, K. M., and Jarvis, B. 2000. Budesonide Inhalation Suspension. Drugs 60:1141-1178.
15. Ilangovan, P., Pedersen, S., Godfrey, S., et al. 1993. Treatment of severe steroid dependent preschool children with nebulised budesonide suspension. Arch. Dis. Child 68:356-359.
16. International consensus report on diagnosis and management of asthma, 1992. Eur. Respir. J: 5:601-641.
17. Kwong, W. T., Ho, S. L., and Coates, A. L. 2000. Comparison of nebulized particle size distribution with Malvern laser diffraction analyzer versus Andersen cascade impactor and low-flow Marple personal cascade impactor. J. Aerosol Med. 13(4):303-14.
18. Lødrup Carlsen, K. C., Nikander, K., and Carlsen, K.-H. 1992. How much nebulised budesonide reaches infants and toddlers? Arch. Dis. Child. 67:1077-1079.
19. Mellon, M., Leflein, J., Walton-Bowen, K., et al. 2000. Comparable efficacy of administration with facemask or mouthpiece of nebulized budesonide inhalation suspension for infants and young children with persistent asthma. Am. J. Respir. Crit. Care Med 162:593-598.
20. Nikander, K., and Bisgaard, H. 1999. Impact of constant and breath-synchronized nebulization on inhaled mass of nebulized budesonide in infants and children. Pediatr. Pulmonol. 28:187-193.
21. Palmer, D., Schurch, S., and Belik, J. 2000. Effect of budesonide and salbutamol on surfactant properties. J. Appl. Physiol. 89:884-890.
22. Pham, S. and Wiedmann, T. S. 2001. Note: dissolution of aerosol particles of budesonide in Survanta™, a model lung surfactant. J. Pharm. Sci. 90:98-103.
23. Szefler, S. J. 1999. Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. J. Allergy Clin. Immunol. 104:S175-S183.
24. Smaldone, G. C., et al. 1998. In vitro determination of inhaled mass and particle distribution for budesonide nebulizing suspension. J. Aerosol Med. 11:113-125.
25. Stapleton, K. W., and Finlay, W. H. 1998. Errors in characterizing nebulized particle size distributions with cascade impactors. J. Aerosol Med. 11:S80-S83.
26. Vikre-Jørgensen, J., Agertoft, L., and Pedersen, S. 1997. Dose titration of nebulized budesonide in young children. Pediatr. Pulmonol. 23:270-277.
27. Wiedmann, T S., Bhatia, R., and Wattenberg, L. W. 2000. Drug solubilization in lung surfactant. J. Control Release 65:43-47.